Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

NCT05767892 is registered in ClinicalTrials.gov with Suzhou Puhe Pharmaceutical Technology Co., LTD as lead sponsor.

NCT NCT05767892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Lead sponsor
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase
Phase 3
Overall status
Not yet recruiting
Start date
May 1, 2023
Completion date
December 31, 2026
Enrollment
350 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic non-small cell lung cancer (nsclc)